Fig. 5.

Transplantation of CD11b/LIF transgenic BMCs into mdx mice reduces muscle fibrosis. a–i TA muscles from WT BMT/mdx (b, e, h) and LIF BMT/mdx transplant recipients (c, f, i) were immunolabeled for collagen types 1 (a–c), 3 (d–f), and 5 (g–i). Bars = 50 µm. The volume fraction of muscle occupied by collagen types 1 (a), 3 (d), and 5 (g) was reduced in LIF BMT/mdx recipients. N = 5 for WT BMT/mdx and LIF BMT/mdx data sets, except n = 4 WT BMT/mdx collagen type 3 and LIF BMT/mdx collagen type 1. * Indicates significantly different from WT BMT/mdx recipients at P < 0.05. F-test collagen type 3 (P = 0.0055) and type 5 (P = 0.0155). For all histograms in the figure, the bars indicate mean ± sem. j QPCR data presented as mean ± sem shows that LIF BMT/mdx recipients also had reduced expression of transcripts encoding Col1a1, Col3a1, and Col5a3. N = 7 or 8 for WT BMT/mdx and LIF BMT/mdx data sets, respectively, except n = 5 for Col5a3 data sets. k QPCR analysis of transcripts associated with the pro-fibrotic Wnt- (Axin2) and TGFβ1-signaling (Tgfb1, Ctgf, Fn1, and Snai1) pathways showed reduced expression of Ctgf, Fn1, and Snai1 in LIF BMT/mdx recipients. N = 7 or 8 for WT BMT/mdx and LIF BMT/mdx data sets, respectively, except n = 7 for LIF BMT/mdx Axin2 group. * Indicates significantly different from WT BMT/mdx recipients at P < 0.05. P-values based on two-tailed t-test. F-test Col1a1 (P = 0.0250). Source data are provided as a Source Data file